| | | | | | | | | | | | | | | | |
| |
 | Issue Date FY: 2025 ( Subtotal = $78,840,646 ) (Continued on the next page) |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Dana-Farber/Harvard Cancer Center | 004 | 60 | NIH | 4/28/2025 | $187,875 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P30CA006516 | Dana-Farber/Harvard Cancer Center | 002 | 60 | NIH | 4/16/2025 | $11,629,721 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA279278 | Sexual Health and Rehabilitation (SHARE): An Online Educational Intervention for Young Adult Female Cancer Survivors | 001 | 2 | NIH | 5/22/2025 | $21,367 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA279278 | Sexual Health and Rehabilitation (SHARE): An Online Educational Intervention for Young Adult Female Cancer Survivors | 000 | 2 | NIH | 4/22/2025 | $192,305 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08HD109453 | Identifying metabolic regulation of T cells during early childhood development | 000 | 2 | NIH | 4/2/2025 | $165,240 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289304 | Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer | 001 | 2 | NIH | 5/22/2025 | $48,749 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289304 | Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer | 000 | 2 | NIH | 4/10/2025 | $438,757 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG086369 | Mitoribosome protein translation signaling and survival mechanisms | 000 | 3 | NIH | 5/2/2025 | $654,606 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG086369 | Mitoribosome protein translation signaling and survival mechanisms | 001 | 3 | NIH | 6/10/2025 | $58,186 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 000 | 3 | NIH | 11/22/2024 | $362,793 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL158269 | Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms | 000 | 5 | NIH | 1/17/2025 | $442,500 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 001 | 9 | NIH | 7/1/2025 | $40,396 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 000 | 9 | NIH | 3/20/2025 | $363,568 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284252 | BH3 Profiling in AML to Measure Apoptotic Signaling Kinetics of Approved Drugs and Identify Integrated Stress Response Apoptotic Susceptibilities | 000 | 3 | NIH | 6/25/2025 | $99,216 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG075837 | Contribution of a novel OPN-producing CD11c+ microglial subset to AD | 000 | 2 | NIH | 12/6/2024 | $455,377 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K23NR020219 | Development and Pilot Testing of a Collaborative Agenda-Setting Intervention to Promote Patient-Centered Communication in Ovarian Cancer Care | 000 | 3 | NIH | 6/9/2025 | $133,300 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 001 | 4 | NIH | 6/10/2025 | $68,012 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 000 | 4 | NIH | 1/15/2025 | $612,114 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA283154 | Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity | 000 | 2 | NIH | 3/4/2025 | $128,798 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289547 | Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors | 002 | 2 | NIH | 7/10/2025 | $685,764 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA298459 | Interrogating the role of IFNgamma in promoting metastasis and immune evasion of triple negative breast cancer | 000 | 1 | NIH | 7/15/2025 | $75,520 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 001 | 2 | NIH | 5/29/2025 | $1,236 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 000 | 2 | NIH | 3/12/2025 | $74,284 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 001 | 5 | NIH | 5/22/2025 | $40,717 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 000 | 5 | NIH | 3/13/2025 | $366,458 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 2 | NIH | 2/13/2025 | $633,159 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 001 | 2 | NIH | 5/22/2025 | $70,351 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 001 | 2 | NIH | 5/22/2025 | $24,678 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 000 | 2 | NIH | 2/13/2025 | $222,106 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 000 | 11 | NIH | 2/28/2025 | $4,683,890 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 000 | 3 | NIH | 2/13/2025 | $99,216 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 000 | 2 | NIH | 3/4/2025 | $632,213 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 001 | 21 | NIH | 3/7/2025 | $416,042 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 001 | 2 | NIH | 5/22/2025 | $70,246 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 002 | 21 | NIH | 5/22/2025 | $46,227 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 001 | 4 | NIH | 5/28/2025 | $52,596 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 000 | 4 | NIH | 3/4/2025 | $473,373 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA259273 | Defining epigenetic mechanisms in NPM1c mutant leukemia | 001 | 5 | NIH | 5/22/2025 | $40,361 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA259273 | Defining epigenetic mechanisms in NPM1c mutant leukemia | 000 | 5 | NIH | 3/3/2025 | $363,246 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31CA301844 | Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | 000 | 1 | NIH | 6/27/2025 | $36,538 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA230503 | Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma | 001 | 7 | NIH | 6/18/2025 | $25,847 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA230503 | Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma | 000 | 7 | NIH | 3/10/2025 | $232,631 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA252639 | Can a subset of patients with HER2+ metastatic breast cancer be cured? | 000 | 5 | NIH | 3/7/2025 | $258,035 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK082889 | Transcriptional control and enhancer recruitment in mouse and human intestinal secretory differentiation | 000 | 13 | NIH | 2/17/2025 | $335,359 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA248727 | Investigating Transcriptional Elongation and Nuclear RNA Surveillance in Melanoma | 000 | 6 | NIH | 3/7/2025 | $195,902 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA300092 | Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | 000 | 1 | NIH | 2/27/2025 | $627,474 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279221 | Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | 001 | 2 | NIH | 5/22/2025 | $72,511 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA283279 | Molecular Dynamics of Glioma Formation and DNA Damage Response by Mutant IDH1 | 000 | 2 | NIH | 3/13/2025 | $299,403 |
| 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1CA233180 | NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | 000 | 6 | NIH | 3/5/2025 | $664,023 |
|